Japan's pharmaceutical manufacturing market is expected to expand from 2026 to 2033, driven by demand for chronic disease treatments resulting from population ageing and the development of innovative biopharmaceuticals. Government measures to strengthen competitiveness and support for overseas expansion are also cited as growth factors.
Japan's pharmaceutical manufacturing market is positioned as a mature market expected to achieve annual growth between 2026 and 2033. Market growth is expected to be driven by rising demand for chronic disease treatments as society continues to age, along with investment in the development of innovative biopharmaceuticals for cancer and autoimmune diseases. Government measures to strengthen competitiveness and regulatory deregulation aimed at developing overseas markets are also expected to support market expansion. Meanwhile, pricing pressure from drug price revisions and tighter safety regulations are recognised as investment risks.
Market segments include small-molecule drugs, biopharmaceuticals, vaccines, sterile injectables, oral solid dosage forms, topical and transdermal formulations, inhaled and intranasal formulations, and active pharmaceutical ingredients. By application, the market covers prescription drugs, over-the-counter drugs, biologics, vaccines, generic drugs, contract development and manufacturing services, hospitals and self-care products. Each category has its own manufacturing requirements and market drivers, while competitiveness depends on technological capabilities, regulatory compliance and supply chain stability.
By region, the market is assumed to have broad coverage across North America, Europe, Asia-Pacific, Latin America, the Middle East and Africa. Japanese companies in particular are expanding in global markets, supported by their advanced technological capabilities and quality control. The use of low-cost production and local partnerships affects competitiveness across regions.
Regarding the need for innovation, both technological innovation and business models are considered important. Progress in ADCs, gene therapy and cell therapy in the biopharmaceutical field, along with the optimisation of manufacturing processes through continuous manufacturing and the use of AI, is identified as playing a central role. Patient-centric services enabled by digitisation and open innovation could create new revenue opportunities, while companies that fall behind are expected to face a greater risk of exiting the market.